Geovax Labs (OTCMKTS:GOVX) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.
This table compares Geovax Labs and Exelixis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Geovax Labs has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.
Institutional & Insider Ownership
0.1% of Geovax Labs shares are owned by institutional investors. Comparatively, 78.4% of Exelixis shares are owned by institutional investors. 2.1% of Geovax Labs shares are owned by company insiders. Comparatively, 4.8% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Geovax Labs and Exelixis’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Geovax Labs||$1.08 million||2.78||-$2.17 million||($0.03)||-0.43|
|Exelixis||$853.83 million||8.00||$690.07 million||$1.43||15.99|
Exelixis has higher revenue and earnings than Geovax Labs. Geovax Labs is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for Geovax Labs and Exelixis, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Exelixis has a consensus price target of $28.38, indicating a potential upside of 24.13%. Given Exelixis’ higher possible upside, analysts clearly believe Exelixis is more favorable than Geovax Labs.
Exelixis beats Geovax Labs on 13 of the 13 factors compared between the two stocks.
About Geovax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.